TcL Pharma appoints board member and operations director

French biotech develops antibodies to treat auto-immune diseases

TcL Pharma, a French biotech company dedicated to the development of antibodies for the treatment of auto-immune diseases has appointed Didier Hoch to its board of directors and Jean-Hugues Masgnaux as operations director.

Hoch has 25 years’ experience in the pharmaceutical industry and in vaccines. Between 2000 and 2010 he ran Sanofi Pasteur MSD, where he led the launch of Gardasil. Prior to this, he carried out various management functions at Rhône Poulenc Rorer (1985-2000), then joined Aventis (Europe, Middle-East/African regions) from 2000 to 2010. He is also a past president (2003-2009) of the European Vaccines Manufacturers Association EVM, and since 2006 has presided over the French Pharmaceutical Companies Association LEEM.

Masgnaux began his career as a consultant at Innothera Laboratories & CNI, going on to become manager of Licences & Agreements at Servier Group and product manager for Fournier Group. Between 1996 and 2000 he progressed from senior product manager to regional sales director and then marketing manager at Bayer Pharma. Between 2000 and 2005 he was Infectiology marketing manager for the France subsidiary of the Gruenenthal group, then international project manager and marketing director. In 2005 he took on the role of president of Madaus Laboratories France, becoming president of the Rottapharm/Madaus Group. In July 2009, he set up M&M Conseil and among other activities works as a health expert for Capgemini Consulting.

You may also like

Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Pharmaceutical

MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients

The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Regulatory

How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Pharmaceutical

White paper: Leadership as the missing control in the Pharmaceutical Quality System (PQS)

Why senior management determines the effectiveness of the pharmaceutical quality system
Regulatory

Oncopeptides to seek EMA label expansion for Pepaxti to include third-line multiple myeloma treatment

The company has said it will submit a Type II variation to the EMA to expand Pepaxti's indication to include patients with multiple myeloma who have received at least two prior lines of therapy — a move that would double the addressable patient population and treatment cycle potential in Europe
Ingredients

The impact of Brexit on raw materials testing for the pharmaceutical industry (2026 update)

Since the UK departed from the EU, the pharmaceutical regulatory landscape has undergone significant and lasting change; whereas early uncertainty has largely subsided, the system has evolved into a stable but more complex dual framework
Subscribe now